iSpecimen Inc. (ISPC) Stock Price & Analysis
iSpecimen Inc. (ISPC) — MoonshotScore 19/100 (Weak band), calculated Nov 18, 2026. Price $0.528 (-0.96%), as of the Nov 19, 2026 trading session; market cap $3.06M.
Educational signal · not a buy or sell recommendation · How to read this
iSpecimen Inc. · ISPC
iSpecimen Inc. operates a marketplace connecting researchers with human biospecimens. The company's technology facilitates the sourcing of biofluids, tissues, and cells for medical research, serving biopharmaceutical, diagnostic, and academic sectors.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · iSpecimen (ISPC)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality and stalling growth, though the balance sheet is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Fair; Growth Durability: Fading; Momentum: Falling.
- quarterly revenue $151,940 (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 6 of the last 8 reports
- Altman Z -16.09 · Piotroski F 4
Holding back: weak fundamentals, soft growth, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 19 | Weak | |
| 19 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.528 | |
| Change on the day | -0.96% | |
| Market capitalisation | $3.06M | — |
| Shares traded on the day | 459.9K |
Price & events
Other perspectives
Council score for iSpecimen (ISPC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is iSpecimen (ISPC), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. iSpecimen Inc. (ISPC) is the company analyzed here. It employs 7 people. In Q2 FY2026 it reported revenue of $151,940 and net income of -$1M. The market values it at $3.06M.
What do the latest results show for iSpecimen (ISPC)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $151,940. Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $151,940 | -$1M | -$0.98 (diluted) |
| Q1 FY2026 | $156,009 | -$2M | -$6.66 (diluted) |
| Q4 FY2025 | $51,761 | -$5M | -$23.59 (diluted) |
| Q3 FY2025 | $106,592 | -$3M | -$19.05 (diluted) |
What are the financial strengths and risks for iSpecimen (ISPC)?
Short answer · as of
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Altman Z -16.09 · Piotroski F 4. Trailing ratios: current ratio 0.82.
How does iSpecimen compare with its peers?
Short answer
iSpecimen's score ranks tied for 2nd of 3 in the bounded comparison shown, against 2 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $0.91 Nov 19, 2026 | $9.76M | 29 5-pillar Nov 18, 2026 | |
| iSpecimen (ISPC) — this page | $0.528 | $3.06M | 19 |
| $2.03 Nov 19, 2026 | $10.1M | 19 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 11
- Purchases
- 2
- Sales
- 0
- Other transactions
- 10
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ISPC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ISPC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about iSpecimen (ISPC)?
- iSpecimen Acquires Two AI Products From Foldlab AI For $4.5M
- iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products
- iSpecimen Inc. Stockholders Approve Reverse Stock Split Proposal
- iSpecimen Expands Healthy Donor Blood Access and Announces AI Development Plans
What Investors Ask About iSpecimen (ISPC)
These answers are editorial: 1 of these 9 answers is drawn from the ISPC research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ISPC?
ISPC carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. iSpecimen Inc. operates a marketplace connecting researchers with human biospecimens.
Is ISPC a good stock to buy?
Stock Expert AI does not rate ISPC buy, sell or hold. iSpecimen Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ISPC stock price today?
The last price recorded for iSpecimen Inc. (ISPC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does iSpecimen Inc. do?
iSpecimen Inc. operates a technology platform, the iSpecimen Marketplace, that connects life science researchers with human biospecimens. The company facilitates the sourcing of biofluids, tissues, and cells from a network of healthcare provider organizations worldwide.
What are the key factors to evaluate for ISPC?
iSpecimen Inc. (ISPC) holds a MoonshotScore in the low range. iSpecimen's technology streamlines the sourcing of human biofluids, tissues, and cells for research. Not financial advice.
How frequently does ISPC data refresh on this page?
ISPC's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ISPC's recent stock price performance?
iSpecimen Inc. (ISPC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary iSpecimen Marketplace platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ISPC overvalued or undervalued right now?
iSpecimen Inc. (ISPC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ISPC before investing?
Before investing in iSpecimen Inc. (ISPC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 9 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com